Patient Profile 2: A 39-Year-Old Woman with High-Risk Stage II CRC

Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Anlotinib/chemotherapy showed comparable efficacy vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.

Updated findings from BREAKWATER support encorafenib plus cetuximab and chemotherapy as a new standard of care in BRAF V600E-mutated metastatic CRC.